Dignitana AB Publishes Q1 2025 Interim Report

Increased turnover – closing in on positive result

.

Financial highlights Q1 2025

• Net Sales amounted to 22.0 MSEK (21.2), an increase of 4 percent over the same quarter in 2024.
• Operating Result amounted to -1.6 MSEK (-5.0).
• Net Result after financial items amounted to -1.9 MSEK (-5.1).
• EBITDA for the first quarter is positive at 0.8 MSEK   (-1.1).
• Earnings per share were –0.02 SEK (-0.07).
• Cash Balance amounted to 2.8 MSEK (2.8).
• Average Daily Treatment Revenue (ADTR)* was 268 TSEK (241) in the quarter

Business highlights during the period

• Dignitana signed a Distribution Agreement for Chronos Trade Medical to be the exclusive provider of DigniCap in Romania.
• Dignitana received a Notice of Allowance from the Korean Intellectual Property Office for a patent titled “Scalp Cooling Apparatus, Method and System.
• Dignitana joined a panel of MedTech leaders to discuss innovation at the Texas BioLife Summit. 

Business highlights after the period

• In April Dignitana exhibited at the Oncology Nursing Society Congress in Denver, Colorado.

Significant events during the period

• Dignitana announced that the Board of Directors unanimously recommended the shareholders accept  the public takeover offer made by Paxman.

Significant events after the period

• Paxman completed the public offer to Dignitana shareholders and extended the acceptance period.
• Dignitana announced an Extraordinary General Meeting is scheduled for 5 June 2025. The EGM is convened at the request of the shareholder Paxman AB (publ) holding more than ten 10 percent of the number of outstanding shares and votes in the Company as of the date of the notice. The Shareholder has requested that the EGM be held to resolve on the dismissal of the Company’s current Board members and to resolve on the number of Board members, election of new Board members and election of a new Chairman of the Board.
• Dignitana announced the Annual General Meeting is scheduled for 26 June 2025. The Notice, which was published 22 May 2025, details numerous proposals for the AGM made by shareholder Paxman AB

Key Figures

* ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.

All financial reports are available at www.dignitana.com/investor-relations/financial-reports/

.

This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 22-05-2025 08:15 CET.

For More Information, Please Contact 

Klas Arildsson, Chairman of the Board of Directors, klas.arildsson@dignitana.com +46 709108003

Fredrik Jonsson, CEO, fredrik.jonsson@dignitana.com  +46 708766444

About Dignitana

Dignitana AB is a Swedish medical technology company specializing in scalp cooling. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and US operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB. Learn more at www.dignitana.com or www.dignicap.com.

Tags: